Agendia Moving to Larger Lab to Keep Pace with Growing MammaPrint Testing Volume
August 11, 2010
Agendia Moving to Larger Lab to Keep Pace with Growing MammaPrint Testing Volume
The company is moving its US operations from an 8,000-square-foot facility in Huntington Beach, Calif., to a 15,000-square foot space in Irvine. The firm also maintains a 13,000-square-foot facility in Amsterdam.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Clarient's Mammostrat to Enter Breast Cancer Recurrence Market as LDT by Fourth Quarter
July 14, 2010 / Pharmacogenomics Reporter - New Releases
April 7, 2010 / Pharmacogenomics Reporter - 'Provocative' Paper Sparks Debate on Relevance of Breast Cancer Gene Expression Signatures
September 4, 2012 / BioArray News - Agendia to Offer FFPE Sample Analysis for Symphony Suite of Breast Cancer Diagnostics
December 21, 2011 / Pharmacogenomics Reporter - Agendia's Pipeline, Test Business Could Benefit From Companion-Dx Deal with AstraZeneca, NKI
May 24, 2011 / BioArray News